Veradermics reports late-stage success for oral minoxidil hair-loss drug
Veradermics said its extended-release oral minoxidil product, VDPHL01, met all primary and secondary endpoints in a late-stage trial. The treatment is an oral version of the long-used hair-regrowth medicine commonly known as Rogaine. The Connecticut biotech is reporting another positive result for the candidate.
Expanded Detail
EXPANDED:
Veradermics, a Connecticut biotechnology company, said its candidate VDPHL01 achieved all primary and secondary goals in an advanced-stage study. The product is an extended-release oral version of minoxidil, the long-used hair-regrowth medicine commonly called Rogaine. The company described this as another favorable outcome for
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Disc Medicine’s rare sun-pain therapy succeeds across Phase 3 endpoints · Drug development
Phase 2 Trial Reports Symptom Gains With Bezisterim in Long COVID · Drug development
Gilead oral IBD therapy clears symptoms in Phase 2 trial · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Veradermics' oral Rogaine wins again at growing hair in late-stage trial.” Browse more stories.